The SARS-CoV-2 pandemic is transitioning into a new phase. Besides long-term effects after infection, researchers are monitoring emerging SARS-CoV-2 variants and their impact on the antiviral immune response as well as vaccine performance.Miltenyi Biotec stands committed to support these studies. We continuously develop new products adjusted to emerging SARS-CoV-2 variants. Furthermore, we provide tools and protocols that are ideally suited for working with infectious material.B cellsSARS-CoV-2 specific B cells and antibodiesT cellsSolutions for stimulation, enrichment, and analysis of rare virus-specific T cellsNK cellsFast isolation and subsequent expansion of NK cellsMyeloid cellsEnrichment and culture of myeloid cells for immunogenicity assays and study of inflammationMACS® Cell Culture and StimulationSARS-CoV-2 PepTivator® Peptide Pools – Virus-specific T cell stimulation – APC loadingMACS® Cell Culture and StimulationAntigens for SARS-CoV-2 research – Investigate virus-specific B cells and antibodiesMACS AntibodiesRecombinant antibodies for immunophenotyping during COVID-19 researchExosomesExosome research solutions for infectious diseaseshttps://www.ancell-bio.com.tw/en/hot_396599.html SARS-CoV-2 research solutions: Helping researchers in their work on viral threats2025-04-072026-04-07
SARS-CoV-2 antigens offer researchers the possibility to investigate virus-specific immune responses, including antigen-specific B cells and antibodies.All our antigens for SARS-CoV-2 research are available in different filling sizes and with or without biotinylation. Recombinantly expressed antigens are tagged with His and AviTag™.Applications of SARS-CoV-2 antigens:Detection of patient-derived antibodiesCharacterization of patient-specific immune responsesDetection and phenotyping of virus-specific B cellsEnrichment of virus-specific B cellsAnalysis of virus binding to host cellsProtein detection assaysSchematic overview of our antigens for SARS-CoV-2 research:This overview illustrates major structural SARS-CoV-2 proteins: The spike protein (S), the nucleoprotein (N), the envelope protein (E), and the membrane protein (M). The spike protein consists of three spike monomers, which form a homotrimeric structure (spike trimer) on the SARS-CoV-2 surface. Each spike monomer consists of an S1 and an S2 subunit, connected at the furin cleavage site. During viral fusion, the receptor binding domain (RBD) binds the host cell target receptor ACE2, whereas the S2 domain mediates membrane fusion.We offer various antigens based on the structural SARS-CoV-2 proteins as well as the target receptor ACE2.Overview of our antigens for SARS-CoV-2 research:Order no.Sequence PartSourceTagBiotinylatedSize (μg)Antigens for SARS-CoV-2 researchRecombinant Human ACE2 130-127-516Q18 to S740 HEKHis, AviTag™No100130-127-456No25130-127-465YES50130-127-442YES10130-127-466Q18 to D615Insect cellsNo100130-127-444No25130-127-464YES50130-127-468 YES10spike Recombinant SARS-CoV-2 Spike-Trimer (HEK) 130-127-683HEKHis, AviTag™NO50130-127-684V16 to K1211 (K986P, V987P, RRAR682–685GSAG), with T4 fibritin trimerization motif NO10130-127-685YES25Recombinant SARS-CoV-2 Spike-Prot (HEK)130-127-680V16 to K1211 HEKHis, AviTag™NO50130-127-681(K986P, V987P, RRAR682–685GSAG) NO10130-127-682YES25Furin cleavage site(and control) SARS-CoV-2 Furin Cleavage Site and SARS-CoV-2 Furin Cleavage Site Control130-127-689S673 to S691 (RRAR) Yes 100130-127-690Yes (FAM-biotin) 100130-127-691S673 to S691 (RRAR682–685GSAG)YES100130-127-692Yes (FAM-biotin) 100Receptor binding domain Recombinant SARS-CoV-2 RBD130-127-518R319 to S591HEKHis, AviTag™No100130-127-448No25130-127-457YES50130-127-458YES10130-127-453Insect cellsNo100130-127-463No25130-127-469YES50130-127-445YES10S domain Recombinant SARS-CoV-2 Spike-S1 (HEK) 130-127-854V16 to P681 HEKHis, AviTag™ NO50130-127-852NO10130-127-853YES25Recombinant SARS-CoV-2 Spike-S2(insect cells) 130-127-686S686 to K1211 (K986P, V987P)Insect cellsHis, AviTag™ NO50130-127-687NO10130-127-688YES25 nucleoprotein Recombinant SARS-CoV-2 Nucleoprotein 130-127-517Full length 130-127-462S2 to A419 HEKHis, AviTag™ NO50130-127-467NO10130-127-454 YES25envelope protein SARS-CoV-2 envelope antigens 130-127-446(Region:C-terminus) L34 to V75NO100130-127-451YES100130-127-455(Region:N-terminus) M1 to S16NO100130-127-461YES100130-127-450(Region:Helical segment 2 (H2)) S55 to V75NO100130-127-452 YES100https://www.ancell-bio.com.tw/en/hot_393281.html Antigens for SARS-CoV-2 research2025-04-072026-04-07
To give you an insight into the latest discoveries on SARS-CoV-2 and promote scientific networking, we hosted a virtual event full of interesting talks and round table discussions with several experts who shared their latest findings in COVID-19 research.Title: Cytokine Capture System for SARS-CoV-2 specific T cellsPresenter: Professor Leung Wing Hang KK Women’s and Children’s Hospital, Singapore.Abstract: SARS-CoV-2-specific T cells are crucial for virus control in COVID-19. A central hypothesis is that SARS-CoV-2 specific T cells from convalescent donors who have recovered from COVID-19 can be manufactured expeditiously and are safe and effective for the treatment of severe SARS-CoV-2 infections in recipients. In this talk, Prof Leung will discuss rapid manufacturing of clinical-grade SARS-CoV-2-specific T cells for adoptive cell therapy. High frequencies of peptide-reactive T cells were found in convalescent donors, regardless of severity of COVID-19. Title: The role of C5a-C5aR1 in COVID-19 Presenter: Professor Eric Vivier Chief Scientific Officer, Innate Pharma. Professor of Immunology, Aix Marseille Université, France.Abstract: COVID-19 is a new pandemic disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).The C5a anaphylatoxin and its receptor C5aR1 (CD88) play a key role in the initiation and maintenance of several inflammatory responses, by recruiting and activating neutrophils and monocytes in the lungs. We provide a longitudinal analysis of immune responses, including immune cell phenotyping and assessments of the soluble factors present in the blood and broncho-alveolar lavage fluid (BALF) of patients at various stages of COVID-19 severity: paucisymptomatic, pneumonia and acute respiratory distress syndrome (ARDS). We report an increase in soluble C5a levels proportional to COVID-19 severity and high levels of C5aR1 expression in blood and pulmonary myeloid cells, supporting a role for the C5a-C5aR1 axis in the pathophysiology of ARDS. Anti-C5aR1 therapeutic monoclonal antibodies (mAbs) prevented C5a-mediated human myeloid cell recruitment and activation and inhibited acute lung injury (ALI) in human C5aR1 knockin mice.These results suggest that C5a-C5aR1 axis blockade might be used as a means of limiting myeloid cell infiltration in damaged organs and preventing the excessive lung inflammation and endothelialitis associated with ARDS in COVID-19 patients.Title: Deep profiling of SARS-CoV-2-specific T cells from healthy donors and COVID-19 patients using ARTEPresenter: Professor Alexander ScheffoldInstitute of Immunology, Christian-Albrechts-Universität zu Kiel, Germany.Abstract: Coronavirus disease 2019 (COVID-19) displays high clinical variability, however the parameters that determine disease severity of COVID-19 are unclear. Pre-existing T cell memory generated by frequent infections with the related “common cold” Coronavirus (CCCoV) has been hypothesized as protective mechanism, but conclusive evidence is lacking. We used antigen-reactive T cell enrichment (ARTE) a sensitive technology to characterize antigen-reactive T cells, to deeply characterize SARS-CoV-2 and CCCoV-specific T cells from healthy donors and COVID-19 patients, using multiparameter cytometry, single cell gene expression profiling and TCR avidity and cross-reactivity measurements. Our data suggests that pre-existing SARS-CoV-2 specific memory is not primarily induced by CCCoV and is not protective, but mainly increased in the elderly. Pre-existing memory may in fact contribute to severe COVID-19 disease observed in this age group. Title: SARS-CoV-2 proteins and analysis of humoral immunity in COVID-19 patientsPresenter: Dr. Susanne BethkeGlobal Product Manager, Miltenyi BiotecAbstract: Cellular and humoral immunity are important immune responses against SARS-CoV-2.Virus clearance and inflammation are mainly mediated by CD8+ T cells directed against the SARS-CoV-2 spike protein. However, the total lymphocyte population, as well as CD4+ T cells, B cells, and natural killer have shown to play a significant role in COVID-19 inflammatory status.Currently it is unknown which responses confer protection against COVID-19.The dynamics of antibody response against SARS-CoV-2 are under investigation and detection of SARS-CoV-2-specific antibodies are no direct indication forprotective immunity. Nevertheless, most of infected patients show an antibody response between day 7 and 21 after infection. Notably, the longevity of the antibody responseis considered to be correlated with protective immunity against reinfections, which is important information when considering the formulation of vaccines.There are still many studies required to fully understand the role of the humoral immune response against SARS-CoV-2. Although serum antibodies are thought to decrease over time, mucosal antibodies, such as IgA, are thought to persist, as demonstrated for seasonal coronavirus 229E. A lot of questions remain unanswered. What level and which type of antibodyis needed for protection? Which target antigenis most protective? What are important antibody dynamics? Which B cells produce these kinds of antibodies? And, might some antibodies enhance the disease? Prolonged studies and more research are therefore required in order to clarify these and many other open questions. To undertake such research, it is vital to have high quality SARS-CoV-2 proteins. We’ll present here the work that has been carried out at Miltenyi Biotec to produce and test full length SARS-CoV-2 proteins and the humoral responses of patients against them.Title: Treg cell therapy as a new approach to prevent the immune hyperactivation responsible for the clinical worsening of COVID-19Presenter: Professor Rafael Correa Rocha Head of Laboratory, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Spain.Abstract: The clinical worsening in COVID-19 patients is a consequence of the immunopathology induced by a cytokine release syndrome, associated with the immune response against the virus, which in the most severe cases can trigger multi-organ failure and death of the patient.Cell therapy with Treg cells can potentially be a successful approach to treat or prevent the immune hyperactivation, and their suppressive capacity can be the best option for the control of the hyperinflammatory phase. Our group has experience in the clinical employment of Treg cell therapy for the control of immune related diseases, employing pioneering approaches that will allow scaling and therapeutic use in large patient groups.Title: Managing cell sorting of biohazardous samples during the COVID-19 pandemicPresenter: David Leclerc CYM(ASCP) Technical Director, Cytometry Antibody Technologies Facility, The University of Chicago, USA.Abstract: The Cytometry and Antibody Technology Facility (CAT) at the University of Chicago received a new MACSQuant Tyto cell sorter in March of 2020, just as the activities in the laboratory were being drastically reduced due to the COVID-19 crisis. Yet, the Tyto became a critical component of the research projects of groups working on that virus. This discussion will provide an overview of the CAT Facility, the circumstances by which the Tyto was acquired, how it became a major part of the way we handle biohazardous material in our research environment, and how we plan to position the Tyto going forward.https://www.ancell-bio.com.tw/en/hot_380682.html Virtual MACS® COVID-19 Day2025-04-072026-04-07
SARS-CoV-2 PepTivator Peptide Pools can be used to investigate T cell immunity in COVID-19 after natural infection or vaccination. Load antigen-presenting cells with the peptides and stimulate SARS-CoV-2–specific T cells. The T cells can then be detected and/or isolated for further research, including analysis of T cell immune response after vaccination or monitoring the immune status after infection. We provide different peptide pools covering specified proteins parts of wild-type and mutated SARS-CoV-2 variants.Application of SARS-CoV-2 PepTivator Peptide PoolsIndividuals recovered from COVID-19 show elevated levels of IFN-γ–producing CD3+ T cells upon stimulation with SARS-CoV-2 PepTivator Peptide PoolsStimulation with SARS-CoV-2 PepTivator Peptide Pools shows the presence of virus-specific T cells in individuals recovered from COVID-19. After stimulation with the peptide pools, intracellular IFN-γ was stained and analyzed in CD3+ T cells using flow cytometry. Samples of a healthy donor and a recovered COVID-19 patient were stimulated for 4 h with the indicated SARS-CoV-2 PepTivator Peptide Pools (Prot_N, Prot_M, Prot_S, or a mix of all three) in the presence of BFA. As negative control, samples were left untreated without (w/o) antigen. Subsequently, T cell lineage surface markers and intracellular cytokines were stained. The presented plots are exemplary data showing IFN-γ+CD3+ T cells. The data demonstrate an increased number of activated T cells in recovered COVID-19 patients upon stimulation with the SARS-CoV-2 peptide pools. Quantitative analysis is shown below.Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.Quantitative analysis of spike protein–specific CD4+ T cells in convalescent COVID-19 donorsBoth options stimulate SARS-CoV-2–reactive T cells to a similar extend as shown by the exemplary analysis of SARS-CoV-2–specific CD4+ T cells in recovered individuals and are suitable for analyzing the immune response upon vaccination with a vaccine based on the spike protein. Samples of a healthy donor and a recovered COVID-19 patient were stimulated with SARS-CoV-2 PepTivator Peptide Pools (Prot_N, Prot_M, Prot_S, or a mix of all three) and examined for IFN-γ production. Stained cells were analyzed using flow cytometry and the frequencies of IFN-γ+CD3+ T cells are shown in the bar chart. Flow data are shown above.Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.Detecting virus-specific T cells after COVID-19 vaccinationSpike protein–reactive T cells were stimulated with PepTivator SARS-CoV-2 Prot_S Complete, which covers the complete sequence of the mature spike protein. Analysis of T cell activation markers illustrates that this PepTivator Peptide Pool is suitable for stimulation of virus-specific CD4+ and CD8+ T cells after COVID-19 vaccination. Samples of a healthy donor and a recovered COVID-19 patient were stimulated with SARS-CoV-2 PepTivator Peptide Pools (mix of Prot_N, Prot_M and Prot_S), left untreated without (w/o) antigens as negative control, or incubated with influenza antigens as positive control. Based on the Rapid ARTE protocol, the cells were subsequently stained (CD3, CD4, CD8, CD154, and TNF-α) and enriched. Cells were gated on CD4+ cells for the presented exemplary flow data. Analysis of CD154 and TNF-α shows successful enrichment of rare SARS-CoV-2–specific CD4+ T cells.Data are kindly provided by Alexander Scheffold and Petra Bacher, UKSH, Kiel, Germany.Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.SARS‑CoV‑2 PepTivator® Peptide Pools Product Information:PepTivator SARS-CoV-2 Prot_S:130-126-700PepTivator SARS-CoV-2 Prot_S, 6 nmol per peptidefor stimulation of 1×10^8 cellsThe PepTivator SARS-CoV-2 Prot_S covers selected immunodominant sequence domains of the spike protein (aa 304–338, 421–475, 492–519, 683–707, 741–770, 785–802, and 885–1273).130-126-701PepTivator SARS-CoV-2 Prot_S, 60 nmol per peptidefor stimulation of 1×10^9 cellsPepTivator SARS-CoV-2 Prot_S1:130-127-041PepTivator SARS-CoV-2 Prot_S1, 6 nmol per peptidefor stimulation of 1×10^8 cells SARS-CoV-2 Prot_S1 covers the complete N-terminal S1 domain of the spike protein (aa 1–692)130-127-048PepTivator SARS-CoV-2 Prot_S1, 60 nmol per peptidefor stimulation of 1×10^9 cellsPepTivator SARS-CoV-2 Prot_S+:130-127-311PepTivator SARS-CoV-2 Prot_S+, 6 nmol per peptidefor stimulation of 1×10^8 cellsSARS-CoV-2 Prot_S+ parts of the C-terminal S2 domain (aa 689–895)130-127-312PepTivator SARS-CoV-2 Prot_S+, 60 nmol per peptidefor stimulation of 1×10^9 cellsPepTivator SARS-CoV-2 Prot_N:130-126-698PepTivator SARS-CoV-2 Prot_N, 6 nmol per peptidefor stimulation of 1×10^8 cellscovering the complete sequence of the nucleocapsid phosphoprotein (“N”) of SARS-Coronavirus 2 (GenBank MN908947.3, Protein QHD43423.2)130-126-699PepTivator SARS-CoV-2 Prot_N, 60 nmol per peptidefor stimulation of 1×10^9 cellsPepTivator SARS-CoV-2 Prot_M:130-126-702PepTivator SARS-CoV-2 Prot_M, 6 nmol per peptidefor stimulation of 1×10^8 cellscovering the complete sequence of the nucleocapsid phosphoprotein (“N”) of SARS-Coronavirus 2 (GenBank MN908947.3, Protein QHD43423.2).130-126-703PepTivator SARS-CoV-2 Prot_M, 60 nmol per peptidefor stimulation of 1×10^9 cellsSchematic alignment of the spike glycoprotein and the SARS‑CoV‑2 PepTivators Prot_S, Prot_S1, and Prot_S+:PepTivator SARS‑CoV‑2 Prot_S covers the predicted immunodominant domains of the SARS‑CoV‑2 spike glycoprotein (protein S), PepTivator SARS‑CoV‑2 Prot_S1 covers the N-terminal S1 domain and PepTivator SARS‑CoV‑2 Prot_S+ covers a part of the C-terminal S2 domain.https://www.ancell-bio.com.tw/en/hot_368479.html Peptide pools for SARS-CoV-2–specific T cell research2025-04-072026-04-07
SARS‑CoV‑2 PepTivator® Peptide PoolsSARS-CoV-2 PepTivator Peptide Pools can be used to investigate T cell immunity in COVID-19 after natural infection or vaccination. Load antigen-presenting cells with the peptides and stimulate SARS-CoV-2–specific T cells. The T cells can then be detected and/or isolated for further research, including analysis of T cell immune response after vaccination or monitoring the immune status after infection. We provide different peptide pools covering specified proteins parts of wild-type and mutated SARS-CoV-2 variants. 0)Fig 1. Lights Clinical Trial For COVID-19 Coronavirus Treatment That ‘Flattens The Curve’ In Patients (Link: https://ppt.cc/fIwlhx)Fig 2. A potent, coronavirus-targeted T-cell product that is safe for patients and has the potential to treat SARS-CoV-2 infections in immunocompromised individuals (Link: https://ppt.cc/fCPpYx)Structure of Coronavirus:SARS‑CoV‑2 PepTivator® Products:Order no.ProductSize130-126-700PepTivator SARS‑CoV‑2 Prot_S6 nmol per peptide pre vial130-126-701PepTivator SARS‑CoV‑2 Prot_S 60 nmol per peptide pre vial130-126-698PepTivator SARS‑CoV‑2 Prot_N6 nmol per peptide pre vial130-126-699PepTivator SARS‑CoV‑2 Prot_N 60 nmol per peptide pre vial130-126-702PepTivator SARS‑CoV‑2 Prot_M6 nmol per peptide pre vial130-126-703PepTivator SARS‑CoV‑2 Prot_M60 nmol per peptide pre vial Antigen-specific in vitro stimulation:Order no.ProductSize130-092-658CD154 Microbeads kitfor positive selection of activated CD154+ antigen-specific CD4+ T cells from human PBMCs130-093-476 CD137 MicroBead Kitfor the positive selection of human CD137+ cells from PBMCs130-054-201IFN-γ Secretion Assayfor the sensitive detection as well as the enrichment of human IFN-γ-secreting cells https://www.ancell-bio.com.tw/en/hot_343654.html Peptide pools to investigate T cell immunity in COVID-192025-04-072026-04-07
Browsing site by scanning QR Code
